<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104845</url>
  </required_header>
  <id_info>
    <org_study_id>03-007</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-IRB-03007</secondary_id>
    <nct_id>NCT00104845</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma</brief_title>
  <official_title>Injection of AJCC Stage IIB, IIC, III, and IV Melanoma Patients With Human and Mouse gp100 DNA: A Phase I Trial to Assess Safety and Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from DNA may make the body build an effective immune response to&#xD;
      kill tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine&#xD;
      therapy in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and feasibility of vaccination with human and mouse gp100 DNA in&#xD;
           patients with stage IIB, IIC, III, or IV melanoma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this regimen in these patients.&#xD;
&#xD;
        -  Compare the antibody and T-cell response in patients treated with two different&#xD;
           vaccination schedules.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess antitumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a randomized, crossover, dose-escalation study. Patients are randomized to 1&#xD;
      of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4,&#xD;
           and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.&#xD;
&#xD;
        -  Arm II: Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients&#xD;
           then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16.&#xD;
&#xD;
      In both arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 6-9 patients (at least 3 per treatment arm) receive escalating doses of human and&#xD;
      mouse gp100 DNA vaccines until the maximum tolerated dose (MTD) is determined. The MTD is&#xD;
      defined as the dose preceding that at which 2 of 9 patients experience dose-limiting&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 weeks and then annually for&#xD;
      15 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 18-27 patients will be accrued for this study within 6-9&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and feasibility</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibody and T-cell response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>human gp100 DNA vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mouse gp100 DNA vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human gp100 plasmid DNA vaccine</intervention_name>
    <arm_group_label>human gp100 DNA vaccine</arm_group_label>
    <arm_group_label>mouse gp100 DNA vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mouse gp100 plasmid DNA vaccine</intervention_name>
    <arm_group_label>human gp100 DNA vaccine</arm_group_label>
    <arm_group_label>mouse gp100 DNA vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant melanoma&#xD;
&#xD;
               -  Stage IIB, IIC, III, or IV disease&#xD;
&#xD;
                    -  Patients with stage III or IV disease who are free of disease after surgical&#xD;
                       resection* are eligible&#xD;
&#xD;
          -  Patients free of disease after surgical resection* must have refused high-dose&#xD;
             interferon alfa OR experienced recurrent disease during prior treatment with&#xD;
             interferon alfa NOTE: *Patients who underwent surgical resection must have had the&#xD;
             surgery within the past year&#xD;
&#xD;
          -  HLA-A0201 positive&#xD;
&#xD;
          -  No detectable brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Albumin ≥ 3.5 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Lactate dehydrogenase ≤ 2 times ULN&#xD;
&#xD;
          -  No clinical history of hepatitis B or C&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No clinical history of HIV&#xD;
&#xD;
          -  No clinical history of HTLV-1&#xD;
&#xD;
          -  No active infection requiring antibiotics within the past 72 hours&#xD;
&#xD;
          -  No history of collagen vascular, rheumatologic, or other autoimmune disorder&#xD;
&#xD;
          -  No grade 1 fever within the past 72 hours&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Weight ≥ 25 kg&#xD;
&#xD;
          -  No serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No preexisting uveal or choroidal eye disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No prior immunization with any class of vaccine containing gp100, including whole&#xD;
             cell, shed antigen, or cell lysate vaccines&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids that would preclude study participation&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No other concurrent medication that would preclude study participation&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent systemic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jedd D. Wolchok, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

